Related Experiment Video
Updated: Oct 13, 2025
Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
Published on: May 21, 2013
Emerging therapies for Achondroplasia: changing the rules of the game
Smitha Kumble1, Ravi Savarirayan1,2
1Murdoch Children's Research Institute, Victorian Clinical Genetics Services, Royal Children's Hospital, Parkville, Australia.
Insights
New precision therapies targeting fibroblast growth factor receptor 3 (FGFR3) are in clinical trials for achondroplasia, offering hope beyond symptomatic treatments for this common genetic cause of short stature.
Area of Science:
- Genetics and Molecular Biology
- Pediatric Endocrinology
- Skeletal Dysplasias
Background:
- Achondroplasia is the most prevalent genetic cause of disproportionate short stature, impacting over 360,000 individuals globally.
- Key complications include cranio-cervical junction compression and obstructive sleep apnea, leading to significant morbidity.
- Current treatments are primarily symptomatic with variable efficacy.
Purpose of the Study:
- To review emerging precision investigational products for achondroplasia.
- To discuss therapies targeting the fibroblast growth factor receptor 3 (FGFR3) pathway.
- To highlight treatments currently in Phase 2 and Phase 3 clinical trials.
Main Methods:
- Review of scientific literature on achondroplasia pathogenesis and therapeutic targets.
- Analysis of ongoing Phase 2 and Phase 3 clinical trials for precision medicines.
- Discussion of molecular pathways involving FGFR3 and fibroblast growth factors (FGFs).
Main Results:
- Development of targeted therapies based on a deeper understanding of FGFR3 molecular pathways.
- Several precision investigational products are advancing through clinical trials.
- These therapies aim to address the underlying mechanisms of achondroplasia.
Conclusions:
- Recent advancements offer potential to alter the natural history of achondroplasia.
- Future research will focus on comparative effectiveness, combination therapies, and long-term benefit-risk profiles.
- Precision medicine represents a paradigm shift in achondroplasia treatment.
Introduction:
Achondroplasia is the most common genetic cause of disproportionate short stature, affecting over 360,000 individuals. Serious complications contributing to significant morbidity in affected individuals include cranio-cervical junction compression and obstructive sleep apnea. Current clinically available treatments are predominantly symptomatic and associated with variable outcomes. We summarize the new precision investigational products that are currently in Phase 2 and Phase 3 clinical trials for the treatment of individuals with achondroplasia.
Areas Covered:
Fibroblast growth factor receptor 3 (FGFR3), a membrane-spanning tyrosine kinase receptor, binds various fibroblast growth factors (FGF) to regulate the normal process of endochondral bone growth. Gain of FGFR3 function in individuals with achondroplasia results in inhibition of normal endochondral ossification. A greater understanding of these molecular pathways through animal models has led to the development of several targeted therapies being tested in children, which we discuss in this review.
Expert Opinion:
The last decade has been game-changing in terms of new precision therapies for children with achondroplasia that have the potential to fundamentally change the natural history of this condition. The next decade will see how these therapies compare, if they might be used in combination, and evaluate the balance of their long-term benefits and harms.
